Search results
Congress Asset Management Co. MA Sells 1,209 Shares of Abbott Laboratories (NYSE:ABT)
ETF DAILY NEWS· 11 hours agoCongress Asset Management Co. MA cut its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 14.9% during the 4th quarter, according to the company in its most ...
Why Bernie Sanders’ Ozempic crusade is misguided
Dallas Morning News· 11 hours agoIt’s not surprising that Sanders, one of the most vociferous critics of the pharmaceutical industry in Congress, would take such a critical approach.
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' - NVIDIA...
Benzinga· 1 day agoOn CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals...
Why are Mustang Bio shares (MBIO) up almost 500%? | Invezz Why are Mustang Bio shares (MBIO) up...
Invezz· 11 hours agoThe pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13...
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 4 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Trump’s Threatened Tariffs Hold Inflation Risk, McCormick Says
Bloomberg via Yahoo News· 50 minutes ago(Bloomberg) -- David McCormick, the former hedge fund executive turned Republican Senate candidate,...
Community pharmacists join the PBM ad frenzy
Politico· 19 hours agoPCMA is...
Who Pays?
The Dispatch via Yahoo News· 11 hours agoIt is an imbecilic idea, and there’s no particular reason to...Trump would seriously pursue it—given that he has rarely seriously pursued substantive...
President Biden Should Pardon D.M. Bennett
Reason.com via Yahoo News· 6 hours agoNow is the time to recognize and remedy past abuses while reaffirming our commitment to the principles of free expression...judgment. He would later...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 21 hours agoAnother next-generation BTK inhibitor competitor to watch for, as first-to-market Imbruvica has lost...
